AstraZeneca diabetes drug granted fast track status for heart failure treatment
AstraZeneca’s diabetes drug, Farxiga, has been granted fast track designation by U.S. regulators for the treatment of heart failure, boosting prospects of wider use of the drug and putting it ahead of rivals.